Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

4510 - Is age a barrier to chemotherapy? Rates of treatment in older patients with breast, colon or lung cancer in England in 2014: a national registry study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cancer in Older Adults

Tumour Site

Breast Cancer;  Colon and Rectal Cancer

Presenters

Nicolò Battisti

Citation

Annals of Oncology (2018) 29 (suppl_8): viii562-viii575. 10.1093/annonc/mdy297

Authors

N.M.L. Battisti1, M. Wallington2, A. Ring1, S. Payne3, R. Birch4, M. Bomb5, J. Seligmann6, T. Kalsi7, L. Hounsome8, D. Dodwell9, S. Underhill10, L. Mensah11, E. Morris12, P.J. Selby6, J. Mansi3

Author affiliations

  • 1 Breast Unit, The Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB
  • 2 National Cancer Registration And Analysis Service, Public Health England, SE1 6LH - London/GB
  • 3 Medical Oncology, Guy's and St Thomas'​ NHS Foundation Trust, London/GB
  • 4 Cancer Epidemiology Group, University of Leeds, Leeds/GB
  • 5 Data Projects, Public Health England, London/GB
  • 6 Oncology, St. James's University Hospital Leeds, LS9 7TF - Leeds/GB
  • 7 Gold Team, Guy's and St Thomas' NHS Foundation Trust, London/GB
  • 8 National Cancer Registration And Analysis Service, Public Health England, London/GB
  • 9 Institute Of Oncology, Leeds Teaching Hospitals NHS Trust, LS9 7TF - Leeds/GB
  • 10 Regional Programmes, Roche, London/GB
  • 11 Health Economics And Outcomes Research, Novartis Oncology, London/GB
  • 12 Cancer Epidemiology Group, University of Leeds, LS9 7TF - Leeds/GB
More

Abstract 4510

Background

Survival from cancer in older patients is poorer in the UK than other countries with similar health systems and wealth possibly due to undertreatment and increased toxicities in this specific population. This population-based observational study describes factors affecting systemic anticancer treatment (SACT) use in older patients in England.

Methods

We identified patients aged ≥70 with stage II-III breast cancer, stage III colon cancer and stage IIIB-IV non-small cell lung cancer (NSCLC) diagnosed in 2014 from a dataset collected by the National Health Service in England. We used logistic regression to estimate factors affecting likelihood of receiving SACT and performed separate regression analyses for each disease, adjusting for age, gender, stage at diagnosis, pathological features, performance status, Charlson comorbidity index, ethnicity and socioeconomic group. We assessed 2-year overall survival (OS) using Kaplan-Meier method. Case mix adjusted treatment rates and workload volume were calculated at hospital level and presented using funnel plots, stratified by age groups (<70 and ≥70) to allow for assessment of variation between centres.

Results

36892 patients were identified: 19879 with stage II-III breast cancer, 5292 with stage III colon cancer and 11721 with stage IIIB-IV NSCLC. Patients over 70 were less likely to receive SACT compared to those aged under 70: breast 11.7% vs 64.6%, p < 0.001; colon 37.4% vs 79%, p < 0.001; NSCLC 33.5% vs 60.2%, p < 0.001. 2-year OS for patients receiving SACT was similar for patients aged ≥70 and <70: breast 91.5% (95% CI: 89.3%-93.2%) vs 96.4% (95% CI: 95.9%-96.7%); colon 84.8% (95% CI: 82.6%-86.8%) vs 88.3% (95% CI: 86.7%-89.8%); NSCLC 16.7% (95% CI: 15.1%-18.4%) vs 19.8% (95%CI: 18.5%-21.1%). Patients receiving SACT had better OS than those untreated. SACT rates varied widely between hospitals after adjusting for case-mix across all ages.

Conclusions

Our study suggests that several factors affect the likelihood of receiving SACT but after adjusting for these, age remains determinant. Identifying hospitals with significantly lower SACT rates should prompt local review of multidisciplinary team practice.

Clinical trial identification

Legal entity responsible for the study

Public Health England.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.